These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 3457438

  • 1. Pharmacokinetic studies on ara-C. With special emphasis on the cellular pharmacokinetics.
    Liliemark J.
    Scand J Haematol Suppl; 1986; 44():41-50. PubMed ID: 3457438
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.
    Wan SH, Huffman DH, Azarnoff DL, Hoogstraten B, Larsen WE.
    Cancer Res; 1974 Feb; 34(2):392-7. PubMed ID: 4521089
    [No Abstract] [Full Text] [Related]

  • 3. [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits].
    Zhou J, Jiang XH, He L, Li CR, Yang JY.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):145-7. PubMed ID: 16468665
    [Abstract] [Full Text] [Related]

  • 4. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP, Willemze R, Honders W, vd Hoorn F, Edelbroek PM.
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [Abstract] [Full Text] [Related]

  • 5. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG.
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA, Beardsley GP, Krikorian JG, Mortara RW, Agarwal RP.
    Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
    [Abstract] [Full Text] [Related]

  • 8. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.
    Sato T, Morozumi M, Kodama K, Kuninaka A, Yoshino H.
    Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
    White JC, Hines LH, Rathmell JP.
    Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
    [Abstract] [Full Text] [Related]

  • 11. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
    Suzuki H, Kim SH, Tanara M, Okazaki K, Okabe T, Wu RT, Tanaka N.
    Cancer Res; 1987 Feb 01; 47(3):713-7. PubMed ID: 3467840
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.
    Karp JE, Donehower RC, Dole GB, Burke PJ.
    Cancer Res; 1984 Nov 01; 44(11):5046-50. PubMed ID: 6488163
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.
    Pommier Y, Pochat L, Marie JP, Zittoun RA.
    Cancer Treat Rep; 1983 Apr 01; 67(4):371-3. PubMed ID: 6850654
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine.
    Kufe D, Herrick D, Crumpacker C, Schnipper L.
    Cancer Res; 1984 Jan 01; 44(1):69-73. PubMed ID: 6317173
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
    Kreis W, Chaudhri F, Chan K, Allen S, Budman DR, Schulman P, Weiselberg L, Freeman J, Deere M, Vinciguerra V.
    Cancer Res; 1985 Dec 01; 45(12 Pt 1):6498-501. PubMed ID: 3864533
    [Abstract] [Full Text] [Related]

  • 20. [The use of the concepts of "half-life" and "clearance" in practice and in pharmacokinetics].
    Raaflaub J.
    Schweiz Med Wochenschr; 1981 Sep 19; 111(38):1406-11. PubMed ID: 7280641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.